Roche’s Gazyva shows superior efficacy in lupus nephritis treatment, Phase III trial data reveals

Roche has announced promising new data from its phase III REGENCY clinical trial, published in the New England Journal of Medicine, highlighting the superior efficacy of Gazyva/Gazyvaro (obinutuzumab) in the treatment of active lupus nephritis. The trial results underscore Gazyva’s potential to significantly improve kidney outcomes in patients with this life-threatening autoimmune conditio